These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 411847)

  • 61. [Bacteriological studies on cefatrizine (S-640 P) (author's transl)].
    Matsuzaki M; Tado N; Hirata Y; Kato M; Nakumura K
    Jpn J Antibiot; 1976 Jan; 29(1):61-8. PubMed ID: 4635
    [No Abstract]   [Full Text] [Related]  

  • 62. [Current status of drug-resistant bacteria and the treatment of refractory infections].
    Matsuda S
    Sanfujinka No Jissai; 1970 Feb; 19(2):182-91. PubMed ID: 4909406
    [No Abstract]   [Full Text] [Related]  

  • 63. Gentamicin: Antibacterial activity in vitro and clinical studies.
    Altucci P; Sapio U; Esposito E
    Chemotherapy; 1965-1966; 10(5):312-20. PubMed ID: 4958548
    [No Abstract]   [Full Text] [Related]  

  • 64. Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic.
    Levison ME; Johnson WD; Thornhill TS; Kaye D
    JAMA; 1969 Sep; 209(9):1331-6. PubMed ID: 4895869
    [No Abstract]   [Full Text] [Related]  

  • 65. [Clinical evaluation of S-6436 in acute simple cystitis: A double blind comparative study of S-6436 and cephalexin (author's transl)].
    Ishigami J; Tanikaze S; Kataoka N; Yamaguchi K; Mita T
    Kansenshogaku Zasshi; 1977 Jun; 51(6):275-85. PubMed ID: 411840
    [No Abstract]   [Full Text] [Related]  

  • 66. [A clinical observation of cefuroxime in pediatric field (author's transl)].
    Ohnuma K; Asuka N; Aoyama R; Nagata K
    Jpn J Antibiot; 1979 Nov; 32(11):1117-21. PubMed ID: 41955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Sensitivity of bacteria causing urinary tract infections towards terizidon (author's transl)].
    Wewalka G; Rotter M; Fischer A
    Wien Klin Wochenschr; 1976 May; 88(11):355-60. PubMed ID: 826024
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cephalexin for oral treatment of canine urinary tract infection caused by Klebsiella pneumoniae.
    Ling GV; Ruby AL
    J Am Vet Med Assoc; 1983 Jun; 182(12):1346-7. PubMed ID: 6348005
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
    Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
    World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical experience with sustained release cephalexin (S-6437) in pediatrics (author's transl)].
    Hori M; Okamoto K; Kohno S
    Jpn J Antibiot; 1978 Feb; 31(2):59-71. PubMed ID: 642208
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). III. Secular changes in susceptibility].
    Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H
    Jpn J Antibiot; 1986 Nov; 39(11):3019-93. PubMed ID: 3102809
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Clinical experience with gentamicin in urinary tract infections (author's transl)].
    Kumazawa J; Nakamuta S; Hieda S; Takesue T
    Jpn J Antibiot; 1976 Mar; 29(3):309-17. PubMed ID: 818418
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical experience with sustained release cefalexin (S-6436) in surgery (author's transl)].
    Takenaka M; Tanimura H; Kamata T; Setoyama M
    Jpn J Antibiot; 1977 Nov; 30(11):893-7. PubMed ID: 592490
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Morphological alterations in Escherichia coli and Serratia marcescens induced by cefotetan (author's transl)].
    Saito M; Saito T; Yano K
    Jpn J Antibiot; 1982 Mar; 35(3):850-5. PubMed ID: 7047794
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Study of nalidixic acid activity on 3186 strains of Gram negative bacilli. Application to the treatment of urinary infections].
    Chamfeuil R; Curcier H
    Presse Med (1893); 1969 Nov; 77(48):1763-4. PubMed ID: 4903534
    [No Abstract]   [Full Text] [Related]  

  • 76. [Clinical trial of HAPA-B in complicated urinary tract infections].
    Kamiryo Y; Kato M; Sanefuji T; Hirao H
    Hinyokika Kiyo; 1986 Sep; 32(9):1379-85. PubMed ID: 3101447
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Evaluation of carbenicillin therapy (author's transl)].
    Sekine O; Usuda Y; Higuchi K; Ono M; Watanabe K
    Jpn J Antibiot; 1974 Feb; 27(1):41-6. PubMed ID: 4210371
    [No Abstract]   [Full Text] [Related]  

  • 78. [Clinical studies on urinary tract infections caused by Serratia marcescens. I. Clinical and bacteriological studies on urinary tract infections caused by Serratia marcescens].
    Sakai S; Kumamoto Y
    Nihon Hinyokika Gakkai Zasshi; 1983 Apr; 74(4):467-84. PubMed ID: 6353020
    [No Abstract]   [Full Text] [Related]  

  • 79. Laboratory and clinical evaluation of rifampicin.
    Atlas E; Turck M
    Am J Med Sci; 1968 Oct; 256(4):47-54. PubMed ID: 4387028
    [No Abstract]   [Full Text] [Related]  

  • 80. Indanyl carbenicillin in chronic recurrent urinary tract infections.
    Seneca H
    J Urol; 1973 Aug; 110(2):249-51. PubMed ID: 4578984
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.